<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01218646</url>
  </required_header>
  <id_info>
    <org_study_id>QIV03</org_study_id>
    <secondary_id>UTN: U1111-1113-3619</secondary_id>
    <nct_id>NCT01218646</nct_id>
  </id_info>
  <brief_title>Study of Quadrivalent Influenza Vaccine Among Adults</brief_title>
  <official_title>Safety and Immunogenicity Trial Among Adults Administered Quadrivalent Influenza Vaccine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi Pasteur, a Sanofi Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to evaluate a prototype quadrivalent influenza vaccine (QIV), the
      licensed 2010-2011 trivalent influenza vaccine (TIV) containing the primary B strain, and the
      investigational TIV containing the alternate B strain in adult subjects.

      Primary Objective:

        -  To demonstrate non-inferiority of antibody responses to QIV compared with licensed
           2010-2011 TIV (containing the primary B strain) and investigational TIV (containing the
           alternate B strain) as assessed by geometric mean titer (GMT) ratios for each of the
           four virus strains separately among subjects 65 years of age and older

      Observational Objective:

        -  To describe the safety profiles of TIV among subjects 18 years of age and older and QIV
           in subjects 65 years and older, as assessed by solicited injection site and systemic
           adverse events (AEs) collected for 7 days post-vaccination, unsolicited adverse events
           collected from 21 days post-vaccination, and adverse events of special interest and
           serious adverse events (SAEs) collected from Visit 1 to Visit 2.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      All participants will receive a single dose of their assigned vaccine during Visit 1. They
      will be followed up for safety and immunogenicity through Day 21 post-vaccination (Visit 2)
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2010</start_date>
  <completion_date type="Actual">April 2011</completion_date>
  <primary_completion_date type="Actual">March 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Geometric Mean Titers Against Influenza B Strains After Vaccination With Fluzone® Quadrivalent Influenza Vaccine or With Trivalent Influenza Vaccines With Corresponding B Strain in Participants Aged 65 Years and Older.</measure>
    <time_frame>Day 21 post-vaccination</time_frame>
    <description>Immunogenicity outcomes were assessed in serum samples by hemagglutination inhibition (HAI) assay. The lower limit of quantitation (LLOQ) was set at the lowest dilution used in the assay, 1/10. Titers below this level were reported as &lt;10.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric Mean Titers Against Influenza B Strains After Vaccination With Fluzone® Quadrivalent Influenza Vaccine or After Trivalent Influenza Vaccines Without Corresponding B Strain in Participants Aged 65 Years and Older.</measure>
    <time_frame>Day 21 post-vaccination</time_frame>
    <description>Immunogenicity outcomes were assessed in serum samples by HAI assay. The lower limit of quantitation (LLOQ) was set at the lowest dilution used in the assay, 1/10. Titers below this level were reported as &lt;10.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric Mean Titers Against the Influenza Virus Antigens After Vaccination With Fluzone® Quadrivalent Influenza Vaccine or Trivalent Influenza Vaccines (TIV) in Participants Aged 18 Years or Older</measure>
    <time_frame>Day 0 and Day 21 post-vaccination</time_frame>
    <description>Immunogenicity outcomes were assessed in serum samples by HAI assay. The lower limit of quantitation (LLOQ) was set at the lowest dilution used in the assay, 1/10. Titers below this level were reported as &lt;10.</description>
  </primary_outcome>
  <other_outcome>
    <measure>Seroconversion Against Influenza B Strains After Vaccination With Fluzone® Quadrivalent Influenza Vaccine or With Trivalent Influenza Vaccines (TIV) With Corresponding B Strains in Participants Aged 65 Years and Older.</measure>
    <time_frame>Day 21 post-vaccination</time_frame>
    <description>Immunogenicity outcomes were assessed in serum samples by HAI assay. The lower limit of quantitation (LLOQ) was set at the lowest dilution used in the assay, 1/10. Titers below this level were reported as &lt; 10.
Seroconversion was defined as either a pre-vaccination HAI titer &lt; 1:10 and a post-vaccination titer ≥1:40 or a pre-vaccination titer ≥1:10 and ≥ four-fold increase in post-vaccination titer.</description>
  </other_outcome>
  <other_outcome>
    <measure>Seroconversion Against Influenza B Strains After Vaccination With Fluzone® Quadrivalent Influenza Vaccine or With Trivalent Influenza Vaccines Without Corresponding B Strain in Participants Aged 65 Years and Older.</measure>
    <time_frame>Day 21 post-vaccination</time_frame>
    <description>Immunogenicity outcomes were assessed in serum samples by HAI assay. The lower limit of quantitation (LLOQ) was set at the lowest dilution used in the assay, 1/10. Titers below this level were reported as &lt;10.
Seroconversion was defined as either a pre-vaccination HAI titer &lt; 1:10 and a post-vaccination titer ≥1:40 or a pre-vaccination titer ≥ 1:10 and ≥ four-fold increase in post-vaccination titers.</description>
  </other_outcome>
  <other_outcome>
    <measure>Seroprotection Against Influenza Vaccine Antigens After Vaccination With Fluzone® Quadrivalent Influenza Vaccine or With Trivalent Influenza Vaccines in Participants Aged 18 Years or Older.</measure>
    <time_frame>Day 21 post-vaccination</time_frame>
    <description>Immunogenicity outcomes were assessed in serum samples by HAI assay. The lower limit of quantitation (LLOQ) was set at the lowest dilution used in the assay, 1/10. Titers below this level were reported as &lt;10.
Seroprotection was defined as a pre-vaccination and post-vaccination titer ≥ 1:40 (l/dil)</description>
  </other_outcome>
  <other_outcome>
    <measure>Seroconversion Against Influenza Virus Antigens After Vaccination With Fluzone® Quadrivalent Influenza Vaccine or With Trivalent Influenza Vaccines in Participants Aged 18 Years and Older</measure>
    <time_frame>Day 21 post-vaccination</time_frame>
    <description>Immunogenicity outcomes were assessed in serum samples by HAI assay. The lower limit of quantitation (LLOQ) was set at the lowest dilution used in the assay, 1/10. Titers below this level were reported as &lt;10.
Seroconversion was defined as either a pre-vaccination HAI titer &lt;1:10 and a post-vaccination titer ≥1:40 or a pre-vaccination titer ≥1:10 and ≥ four-fold increase in post-vaccination titer.</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of Participants Reporting Solicited Injection Site and Systemic Reactions After Vaccination With Fluzone® Quadrivalent Influenza Vaccine or With Trivalent Influenza Vaccines.</measure>
    <time_frame>Day 0 up to day 21 post-vaccination</time_frame>
    <description>Solicited injection site reactions: Pain, Erythema and Swelling; Solicited systemic reactions: Fever (Temperature), Headache, Malaise, and Myalgia.
Grade 3 Injection site reactions: Pain - Significant; prevents daily activity; Erythema and Swelling &gt;100 mm.
Grade 3 solicited systemic reactions: Fever (Temperature) ≥102.1°F; Headache, Malaise, and Myalgia - Significant; prevents daily activity.</description>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">739</enrollment>
  <condition>Influenza</condition>
  <arm_group>
    <arm_group_label>Group 1: Investigational Quadrivalent Influenza Vaccine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive a dose of Investigational Quadrivalent Inactivated Influenza Vaccine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2: Investigational Trivalent Influenza Vaccine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive a dose of Investigational Trivalent Inactivated Influenza Vaccine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3: Licensed 2010-2011 Trivalent Influenza Vaccine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will receive a dose of Licensed 2010-2011 Trivalent Inactivated Influenza Vaccine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 4: Licensed 2010-2011 Trivalent Influenza Vaccine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will receive a dose of Licensed 2010-2011 Trivalent Inactivated Influenza Vaccine</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Investigational Quadrivalent Inactivated Influenza Vaccine, No Preservative</intervention_name>
    <description>0.5 mL, Intramuscular</description>
    <arm_group_label>Group 1: Investigational Quadrivalent Influenza Vaccine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Investigational Trivalent Inactivated Influenza Vaccine, No Preservative</intervention_name>
    <description>0.5 mL, Intramuscular</description>
    <arm_group_label>Group 2: Investigational Trivalent Influenza Vaccine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Fluzone®: 2010-2011 Trivalent Inactivated Influenza Vaccine, No Preservative</intervention_name>
    <description>0.5 mL, Intramuscular</description>
    <arm_group_label>Group 3: Licensed 2010-2011 Trivalent Influenza Vaccine</arm_group_label>
    <other_name>Fluzone®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Fluzone®: 2010-2011 Trivalent Inactivated Influenza Vaccine, No Preservative</intervention_name>
    <description>0.5 mL, Intramuscular</description>
    <arm_group_label>Group 4: Licensed 2010-2011 Trivalent Influenza Vaccine</arm_group_label>
    <other_name>Fluzone®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Subject is 18 years of age or older on the day of inclusion.

          -  Informed consent form (ICF) has been signed and dated.

          -  Able to attend all scheduled visits and to comply with all trial procedures.

          -  For a woman of childbearing potential, use of an effective method of contraception or
             abstinence from at least 4 weeks prior to the first vaccination until at least 4 weeks
             post-vaccination.

        Exclusion criteria:

          -  Known pregnancy, or a positive urine pregnancy test.

          -  Currently breastfeeding a child.

          -  History of serious adverse reaction to any influenza vaccine.

          -  Receipt of any vaccine in the 4 weeks preceding the trial vaccination.

          -  Planned receipt of any vaccine between Visit 1 and Visit 2.

          -  Participation in another interventional clinical trial investigating a vaccine, drug,
             medical device, or medical procedure in the 4 weeks preceding the first study
             vaccination or during the course of the study.

          -  Receipt of any influenza vaccine since 01 August 2010 (including 2009 H1N1 monovalent
             vaccine).

          -  Known systemic hypersensitivity to any of the vaccine components, or history of a
             life-threatening reaction to the vaccine(s) used in the trial or to a vaccine
             containing any of the same substances.

          -  Receipt of blood or blood-derived products in the past 3 months, which might interfere
             with assessment of the immune response.

          -  Thrombocytopenia, bleeding disorder, or receipt of anticoagulants contraindicating
             intramuscular vaccination.

          -  Any condition that in the opinion of the Investigator would pose a health risk to the
             subject if enrolled or could interfere with the evaluation of the vaccine.

          -  Personal history of Guillain-Barré Syndrome (GBS).

          -  Known or suspected congenital or acquired immunodeficiency; or receipt of
             immunosuppressive therapy such as anti-cancer chemotherapy or radiation therapy within
             the preceding 6 months; or long-term systemic corticosteroid therapy (prednisone or
             equivalent for more than 2 consecutive weeks within the past 3 months).

          -  Any chronic illness that, in the opinion of the Investigator, is not well controlled
             or that may interfere with trial conduct or completion or with assessment of adverse
             events.

          -  Known seropositivity for human immunodeficiency virus (HIV), hepatitis B, or hepatitis
             C.

          -  Deprived of freedom by an administrative or court order, or in an emergency setting,
             or hospitalized involuntarily.

          -  Current alcohol or drug use that, in the opinion of the Investigator, might interfere
             with the ability to comply with trial procedures.

          -  Identified as employees of the Investigator or study center, with direct involvement
             in the proposed study or other studies under the direction of that Investigator or
             study center, as well as family members (i.e., immediate, husband, wife and their
             children, adopted or natural) of the employees or the Investigator.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi Pasteur Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Hoover</city>
        <state>Alabama</state>
        <zip>35216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>South Miami</city>
        <state>Florida</state>
        <zip>33143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Springfield</city>
        <state>Missouri</state>
        <zip>65802</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10004</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45249</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Allentown</city>
        <state>Pennsylvania</state>
        <zip>18102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bensalem</city>
        <state>Pennsylvania</state>
        <zip>19020</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Warwick</city>
        <state>Rhode Island</state>
        <zip>02866</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mt. Pleasant</city>
        <state>South Carolina</state>
        <zip>29464</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.sanofipasteur.com</url>
  </link>
  <link>
    <url>http://www.sanofiaventis.com</url>
  </link>
  <verification_date>September 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 8, 2010</study_first_submitted>
  <study_first_submitted_qc>October 8, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 11, 2010</study_first_posted>
  <results_first_submitted>July 3, 2013</results_first_submitted>
  <results_first_submitted_qc>July 3, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 12, 2013</results_first_posted>
  <disposition_first_submitted>December 12, 2011</disposition_first_submitted>
  <disposition_first_submitted_qc>December 12, 2011</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">December 22, 2011</disposition_first_posted>
  <last_update_submitted>September 13, 2013</last_update_submitted>
  <last_update_submitted_qc>September 13, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 23, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Influenza</keyword>
  <keyword>Quadrivalent Inactivated Influenza Vaccine</keyword>
  <keyword>Trivalent Inactivated Influenza Vaccine</keyword>
  <keyword>Influenza viruses</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The study participants were enrolled from 08 October through 01 December 2010 in 12 clinic centers in the US.</recruitment_details>
      <pre_assignment_details>A total of 739 participants who met all the inclusion criteria and none of the exclusion criteria were enrolled, randomized and vaccinated in the study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Group 1 (Investigational Quadrivalent Influenza Vaccine)</title>
          <description>Participants aged 65 years and older who received the Investigational Quadrivalent Influenza Vaccine</description>
        </group>
        <group group_id="P2">
          <title>Group 2 (Investigational Trivalent Influenza Vaccine)</title>
          <description>Participants aged 65 years and older who received the Investigational Trivalent Influenza Vaccine</description>
        </group>
        <group group_id="P3">
          <title>Group 3 (Licensed Trivalent Influenza Vaccine)</title>
          <description>Participants aged 65 years and older who received the Licensed 2010-2011 Trivalent Influenza Vaccine</description>
        </group>
        <group group_id="P4">
          <title>Group 4 (Licensed Trivalent Influenza Vaccine)</title>
          <description>Participants aged 18 to less than 65 years who received the Licensed 2010-2011 Trivalent Influenza Vaccine.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="225"/>
                <participants group_id="P2" count="225"/>
                <participants group_id="P3" count="225"/>
                <participants group_id="P4" count="64"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="224"/>
                <participants group_id="P2" count="225"/>
                <participants group_id="P3" count="223"/>
                <participants group_id="P4" count="63"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Group 1 (Investigational Quadrivalent Influenza Vaccine)</title>
          <description>Participants aged 65 years and older who received the Investigational Quadrivalent Influenza Vaccine</description>
        </group>
        <group group_id="B2">
          <title>Group 2 (Investigational Trivalent Influenza Vaccine)</title>
          <description>Participants aged 65 years and older who received the Investigational Trivalent Influenza Vaccine</description>
        </group>
        <group group_id="B3">
          <title>Group 3 (Licensed Trivalent Influenza Vaccine)</title>
          <description>Participants aged 65 years and older who received the received the Licensed 2010-2011 Trivalent Influenza Vaccine</description>
        </group>
        <group group_id="B4">
          <title>Group 4 (Licensed Trivalent Influenza Vaccine)</title>
          <description>Participants aged 18 to less than 65 years who received the Licensed 2010-2011 Trivalent Influenza Vaccine</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="225"/>
            <count group_id="B2" value="225"/>
            <count group_id="B3" value="225"/>
            <count group_id="B4" value="64"/>
            <count group_id="B5" value="739"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="64"/>
                    <measurement group_id="B5" value="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="225"/>
                    <measurement group_id="B2" value="225"/>
                    <measurement group_id="B3" value="225"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="675"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="72.4" spread="5.7"/>
                    <measurement group_id="B2" value="72.8" spread="5.6"/>
                    <measurement group_id="B3" value="72.8" spread="5.3"/>
                    <measurement group_id="B4" value="46.0" spread="11.6"/>
                    <measurement group_id="B5" value="70.4" spread="9.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="129"/>
                    <measurement group_id="B2" value="121"/>
                    <measurement group_id="B3" value="126"/>
                    <measurement group_id="B4" value="27"/>
                    <measurement group_id="B5" value="403"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="96"/>
                    <measurement group_id="B2" value="104"/>
                    <measurement group_id="B3" value="99"/>
                    <measurement group_id="B4" value="37"/>
                    <measurement group_id="B5" value="336"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="225"/>
                    <measurement group_id="B2" value="225"/>
                    <measurement group_id="B3" value="225"/>
                    <measurement group_id="B4" value="64"/>
                    <measurement group_id="B5" value="739"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean Titers Against Influenza B Strains After Vaccination With Fluzone® Quadrivalent Influenza Vaccine or With Trivalent Influenza Vaccines With Corresponding B Strain in Participants Aged 65 Years and Older.</title>
        <description>Immunogenicity outcomes were assessed in serum samples by hemagglutination inhibition (HAI) assay. The lower limit of quantitation (LLOQ) was set at the lowest dilution used in the assay, 1/10. Titers below this level were reported as &lt;10.</description>
        <time_frame>Day 21 post-vaccination</time_frame>
        <population>Geometric mean titers to the influenza vaccine B antigens were determined in randomized and vaccinated participants, per-protocol population. Data presented for participants with valid serology results for the B antigens, including results reported as less or greater than lower limit of quantitation (&lt;LLOQ or &gt;ULOQ).</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1 (Investigational Quadrivalent Influenza Vaccine)</title>
            <description>Participants aged 65 years and older who received the Investigational Quadrivalent Influenza Vaccine</description>
          </group>
          <group group_id="O2">
            <title>Group 2 (Investigational Trivalent Influenza Vaccine)</title>
            <description>Participants aged 65 years and older who received the Investigational Trivalent Influenza Vaccine</description>
          </group>
          <group group_id="O3">
            <title>Group 3 (Licensed Trivalent Influenza Vaccine)</title>
            <description>Participants aged 65 years and older who received the Licensed 2010-2011 Trivalent Influenza Vaccine</description>
          </group>
          <group group_id="O4">
            <title>Group 4 (Licensed Trivalent Influenza Vaccine)</title>
            <description>Participants aged 18 to less than 65 years who received the Licensed 2010-2011 Trivalent Influenza Vaccine</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Titers Against Influenza B Strains After Vaccination With Fluzone® Quadrivalent Influenza Vaccine or With Trivalent Influenza Vaccines With Corresponding B Strain in Participants Aged 65 Years and Older.</title>
          <description>Immunogenicity outcomes were assessed in serum samples by hemagglutination inhibition (HAI) assay. The lower limit of quantitation (LLOQ) was set at the lowest dilution used in the assay, 1/10. Titers below this level were reported as &lt;10.</description>
          <population>Geometric mean titers to the influenza vaccine B antigens were determined in randomized and vaccinated participants, per-protocol population. Data presented for participants with valid serology results for the B antigens, including results reported as less or greater than lower limit of quantitation (&lt;LLOQ or &gt;ULOQ).</population>
          <units>Titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="220"/>
                <count group_id="O2" value="221"/>
                <count group_id="O3" value="219"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>B/Brisbane/60/2008 (220, 0, 219, 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.8" lower_limit="63.9" upper_limit="85.3"/>
                    <measurement group_id="O2" value="NA">B/Brisbane/60/2008 influenza virus antigen was not in the vaccine administered to this group</measurement>
                    <measurement group_id="O3" value="57.9" lower_limit="50.6" upper_limit="66.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Florida/04/2006 (220, 221, 0, 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.1" lower_limit="52.5" upper_limit="71.2"/>
                    <measurement group_id="O2" value="54.8" lower_limit="47.5" upper_limit="63.3"/>
                    <measurement group_id="O3" value="NA">B/Florida/04/2006 influenza virus antigen was not in the vaccine administered to this group</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Seroconversion Against Influenza B Strains After Vaccination With Fluzone® Quadrivalent Influenza Vaccine or With Trivalent Influenza Vaccines (TIV) With Corresponding B Strains in Participants Aged 65 Years and Older.</title>
        <description>Immunogenicity outcomes were assessed in serum samples by HAI assay. The lower limit of quantitation (LLOQ) was set at the lowest dilution used in the assay, 1/10. Titers below this level were reported as &lt; 10.
Seroconversion was defined as either a pre-vaccination HAI titer &lt; 1:10 and a post-vaccination titer ≥1:40 or a pre-vaccination titer ≥1:10 and ≥ four-fold increase in post-vaccination titer.</description>
        <time_frame>Day 21 post-vaccination</time_frame>
        <population>Seroconversion with respect to influenza vaccine B strains (corresponding B strains) was determined in randomized and vaccinated adult participants, per-protocol population</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1 (Investigational Quadrivalent Influenza Vaccine)</title>
            <description>Participants aged 65 years and older who received the Investigational Quadrivalent Influenza Vaccine</description>
          </group>
          <group group_id="O2">
            <title>Group 2 (Investigational Trivalent Influenza Vaccine)</title>
            <description>Participants aged 65 years and older who received the Investigational Trivalent Influenza Vaccine</description>
          </group>
          <group group_id="O3">
            <title>Group 3 (Licensed Trivalent Influenza Vaccine)</title>
            <description>Participants aged 65 years and older who received the Licensed 2010-2011 Trivalent Influenza Vaccine</description>
          </group>
          <group group_id="O4">
            <title>Group 4 (Licensed Trivalent Influenza Vaccine)</title>
            <description>Participants aged 18 to less than 65 years who received the Licensed 2010-2011 Trivalent Influenza Vaccine</description>
          </group>
        </group_list>
        <measure>
          <title>Seroconversion Against Influenza B Strains After Vaccination With Fluzone® Quadrivalent Influenza Vaccine or With Trivalent Influenza Vaccines (TIV) With Corresponding B Strains in Participants Aged 65 Years and Older.</title>
          <description>Immunogenicity outcomes were assessed in serum samples by HAI assay. The lower limit of quantitation (LLOQ) was set at the lowest dilution used in the assay, 1/10. Titers below this level were reported as &lt; 10.
Seroconversion was defined as either a pre-vaccination HAI titer &lt; 1:10 and a post-vaccination titer ≥1:40 or a pre-vaccination titer ≥1:10 and ≥ four-fold increase in post-vaccination titer.</description>
          <population>Seroconversion with respect to influenza vaccine B strains (corresponding B strains) was determined in randomized and vaccinated adult participants, per-protocol population</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="220"/>
                <count group_id="O2" value="221"/>
                <count group_id="O3" value="219"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>B/Brisbane/60/2008 (220, 0, 219, 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63"/>
                    <measurement group_id="O2" value="NA">B/Brisbane/60/2008 influenza virus antigen was not in the vaccine administered to this group</measurement>
                    <measurement group_id="O3" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Florida/04/2006 (220, 221, 0, 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73"/>
                    <measurement group_id="O2" value="69" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="NA" lower_limit="0" upper_limit="0">B/Florida/04/2006 influenza virus antigen was not in the vaccine administered to this group</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean Titers Against Influenza B Strains After Vaccination With Fluzone® Quadrivalent Influenza Vaccine or After Trivalent Influenza Vaccines Without Corresponding B Strain in Participants Aged 65 Years and Older.</title>
        <description>Immunogenicity outcomes were assessed in serum samples by HAI assay. The lower limit of quantitation (LLOQ) was set at the lowest dilution used in the assay, 1/10. Titers below this level were reported as &lt;10.</description>
        <time_frame>Day 21 post-vaccination</time_frame>
        <population>Geometric Mean Titers to the influenza vaccine B strains (cross-reactive antibody) were determined in randomized and vaccinated participants, per-protocol population</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1 (Investigational Quadrivalent Influenza Vaccine)</title>
            <description>Participants aged 65 years and older who received the Investigational Quadrivalent Influenza Vaccine</description>
          </group>
          <group group_id="O2">
            <title>Group 2 (Investigational Trivalent Influenza Vaccine)</title>
            <description>Participants aged 65 years and older who received the Investigational Trivalent Influenza Vaccine</description>
          </group>
          <group group_id="O3">
            <title>Group 3 (Licensed Trivalent Influenza Vaccine)</title>
            <description>Participants aged 65 years and older who received the Licensed 2010-2011 Trivalent Influenza Vaccine</description>
          </group>
          <group group_id="O4">
            <title>Group 4 (Licensed Trivalent Influenza Vaccine)</title>
            <description>Participants aged 18 to less than 65 years who received the Licensed 2010-2011 Trivalent Influenza Vaccine</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Titers Against Influenza B Strains After Vaccination With Fluzone® Quadrivalent Influenza Vaccine or After Trivalent Influenza Vaccines Without Corresponding B Strain in Participants Aged 65 Years and Older.</title>
          <description>Immunogenicity outcomes were assessed in serum samples by HAI assay. The lower limit of quantitation (LLOQ) was set at the lowest dilution used in the assay, 1/10. Titers below this level were reported as &lt;10.</description>
          <population>Geometric Mean Titers to the influenza vaccine B strains (cross-reactive antibody) were determined in randomized and vaccinated participants, per-protocol population</population>
          <units>Titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="220"/>
                <count group_id="O2" value="221"/>
                <count group_id="O3" value="219"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>B/Brisbane/60/2008 (220, 221, 0, 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.8" lower_limit="63.9" upper_limit="85.3"/>
                    <measurement group_id="O2" value="42.2" lower_limit="36.5" upper_limit="48.7"/>
                    <measurement group_id="O3" value="NA">B/Brisbane/60/2008 influenza virus antigen was not in the vaccine administered to this group</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Florida/04/2006 (220, 0, 219, 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.1" lower_limit="52.5" upper_limit="71.2"/>
                    <measurement group_id="O2" value="NA">B/Florida/04/2006 influenza virus antigen was not in the vaccine administered to this group</measurement>
                    <measurement group_id="O3" value="28.5" lower_limit="24.6" upper_limit="33.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Seroconversion Against Influenza B Strains After Vaccination With Fluzone® Quadrivalent Influenza Vaccine or With Trivalent Influenza Vaccines Without Corresponding B Strain in Participants Aged 65 Years and Older.</title>
        <description>Immunogenicity outcomes were assessed in serum samples by HAI assay. The lower limit of quantitation (LLOQ) was set at the lowest dilution used in the assay, 1/10. Titers below this level were reported as &lt;10.
Seroconversion was defined as either a pre-vaccination HAI titer &lt; 1:10 and a post-vaccination titer ≥1:40 or a pre-vaccination titer ≥ 1:10 and ≥ four-fold increase in post-vaccination titers.</description>
        <time_frame>Day 21 post-vaccination</time_frame>
        <population>Seroconversion to influenza vaccine B Strains (cross-reactive antibody) was determined in randomized and vaccinated participants, per-protocol population</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1 (Investigational Quadrivalent Influenza Vaccine)</title>
            <description>Participants aged 65 years and older who received the Investigational Quadrivalent Influenza Vaccine</description>
          </group>
          <group group_id="O2">
            <title>Group 2 (Investigational Trivalent Influenza Vaccine)</title>
            <description>Participants aged 65 years and older who received the Investigational Trivalent Influenza Vaccine</description>
          </group>
          <group group_id="O3">
            <title>Group 3 (Licensed Trivalent Influenza Vaccine)</title>
            <description>Participants aged 65 years and older who received the Licensed 2010-2011 Trivalent Influenza Vaccine</description>
          </group>
          <group group_id="O4">
            <title>Group 4 (Licensed Trivalent Influenza Vaccine)</title>
            <description>Participants aged 18 to less than 65 years who received the Licensed 2010-2011 Trivalent Influenza Vaccine</description>
          </group>
        </group_list>
        <measure>
          <title>Seroconversion Against Influenza B Strains After Vaccination With Fluzone® Quadrivalent Influenza Vaccine or With Trivalent Influenza Vaccines Without Corresponding B Strain in Participants Aged 65 Years and Older.</title>
          <description>Immunogenicity outcomes were assessed in serum samples by HAI assay. The lower limit of quantitation (LLOQ) was set at the lowest dilution used in the assay, 1/10. Titers below this level were reported as &lt;10.
Seroconversion was defined as either a pre-vaccination HAI titer &lt; 1:10 and a post-vaccination titer ≥1:40 or a pre-vaccination titer ≥ 1:10 and ≥ four-fold increase in post-vaccination titers.</description>
          <population>Seroconversion to influenza vaccine B Strains (cross-reactive antibody) was determined in randomized and vaccinated participants, per-protocol population</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="220"/>
                <count group_id="O2" value="221"/>
                <count group_id="O3" value="219"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>B/Brisbane/60/2008 (220, 221, 0, 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63"/>
                    <measurement group_id="O2" value="19"/>
                    <measurement group_id="O3" value="NA">B/Brisbane/60/2008 influenza virus antigen was not in the vaccine administered to this group.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Florida/04/2006 (220, 0, 219, 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73"/>
                    <measurement group_id="O2" value="NA" lower_limit="0" upper_limit="0">B/Florida/04/2006 influenza virus antigen was not in the vaccine administered to this group.</measurement>
                    <measurement group_id="O3" value="20" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean Titers Against the Influenza Virus Antigens After Vaccination With Fluzone® Quadrivalent Influenza Vaccine or Trivalent Influenza Vaccines (TIV) in Participants Aged 18 Years or Older</title>
        <description>Immunogenicity outcomes were assessed in serum samples by HAI assay. The lower limit of quantitation (LLOQ) was set at the lowest dilution used in the assay, 1/10. Titers below this level were reported as &lt;10.</description>
        <time_frame>Day 0 and Day 21 post-vaccination</time_frame>
        <population>Geometric Mean Titers to the influenza vaccine antigens were determined in randomized and vaccinated participants, per-protocol population</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1 (Investigational Quadrivalent Influenza Vaccine)</title>
            <description>Participants aged 65 years and older who received the Investigational Quadrivalent Influenza Vaccine</description>
          </group>
          <group group_id="O2">
            <title>Group 2 (Investigational Trivalent Influenza Vaccine)</title>
            <description>Participants aged 65 years and older who received the Investigational Trivalent Influenza Vaccine</description>
          </group>
          <group group_id="O3">
            <title>Group 3 (Licensed Trivalent Influenza Vaccine)</title>
            <description>Participants aged 65 years and older who received the Licensed 2010-2011 Trivalent Influenza Vaccine</description>
          </group>
          <group group_id="O4">
            <title>Group 4 (Licensed Trivalent Influenza Vaccine)</title>
            <description>Participants aged 18 to less than 65 years who received the Licensed 2010-2011 Trivalent Influenza Vaccine</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Titers Against the Influenza Virus Antigens After Vaccination With Fluzone® Quadrivalent Influenza Vaccine or Trivalent Influenza Vaccines (TIV) in Participants Aged 18 Years or Older</title>
          <description>Immunogenicity outcomes were assessed in serum samples by HAI assay. The lower limit of quantitation (LLOQ) was set at the lowest dilution used in the assay, 1/10. Titers below this level were reported as &lt;10.</description>
          <population>Geometric Mean Titers to the influenza vaccine antigens were determined in randomized and vaccinated participants, per-protocol population</population>
          <units>Titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="220"/>
                <count group_id="O2" value="221"/>
                <count group_id="O3" value="219"/>
                <count group_id="O4" value="59"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/H1N1, Pre-vaccination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.7" lower_limit="17.9" upper_limit="26.3"/>
                    <measurement group_id="O2" value="21.1" lower_limit="17.5" upper_limit="25.5"/>
                    <measurement group_id="O3" value="24.8" lower_limit="20.4" upper_limit="30.1"/>
                    <measurement group_id="O4" value="26.7" lower_limit="17.7" upper_limit="40.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H1N1, Post-vaccination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="231" lower_limit="188" upper_limit="283"/>
                    <measurement group_id="O2" value="271" lower_limit="221" upper_limit="331"/>
                    <measurement group_id="O3" value="269" lower_limit="221" upper_limit="328"/>
                    <measurement group_id="O4" value="728" lower_limit="515" upper_limit="1030"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2, Pre-vaccination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.3" lower_limit="42.1" upper_limit="65.0"/>
                    <measurement group_id="O2" value="42.3" lower_limit="34.9" upper_limit="51.4"/>
                    <measurement group_id="O3" value="48.3" lower_limit="40.0" upper_limit="58.4"/>
                    <measurement group_id="O4" value="33.0" lower_limit="22.1" upper_limit="49.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2, Post vaccination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="501" lower_limit="422" upper_limit="593"/>
                    <measurement group_id="O2" value="360" lower_limit="302" upper_limit="429"/>
                    <measurement group_id="O3" value="291" lower_limit="243" upper_limit="347"/>
                    <measurement group_id="O4" value="503" lower_limit="361" upper_limit="701"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Brisbane, Pre-vaccination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.1" lower_limit="23.3" upper_limit="31.5"/>
                    <measurement group_id="O2" value="28.5" lower_limit="24.2" upper_limit="33.6"/>
                    <measurement group_id="O3" value="29.0" lower_limit="25.0" upper_limit="33.7"/>
                    <measurement group_id="O4" value="18.9" lower_limit="14.0" upper_limit="25.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Brisbane, Post-vaccination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.8" lower_limit="63.9" upper_limit="85.3"/>
                    <measurement group_id="O2" value="42.2" lower_limit="36.5" upper_limit="48.7"/>
                    <measurement group_id="O3" value="57.9" lower_limit="50.6" upper_limit="66.4"/>
                    <measurement group_id="O4" value="97.7" lower_limit="75.0" upper_limit="127"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Florida, Pre-vaccination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.2" lower_limit="17.5" upper_limit="23.3"/>
                    <measurement group_id="O2" value="19.7" lower_limit="17.2" upper_limit="22.6"/>
                    <measurement group_id="O3" value="18.7" lower_limit="16.4" upper_limit="21.3"/>
                    <measurement group_id="O4" value="19.5" lower_limit="14.5" upper_limit="26.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Florida, Post-vaccination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.1" lower_limit="52.5" upper_limit="71.2"/>
                    <measurement group_id="O2" value="54.8" lower_limit="47.5" upper_limit="63.3"/>
                    <measurement group_id="O3" value="28.5" lower_limit="24.6" upper_limit="33.0"/>
                    <measurement group_id="O4" value="48.6" lower_limit="35.5" upper_limit="66.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Seroprotection Against Influenza Vaccine Antigens After Vaccination With Fluzone® Quadrivalent Influenza Vaccine or With Trivalent Influenza Vaccines in Participants Aged 18 Years or Older.</title>
        <description>Immunogenicity outcomes were assessed in serum samples by HAI assay. The lower limit of quantitation (LLOQ) was set at the lowest dilution used in the assay, 1/10. Titers below this level were reported as &lt;10.
Seroprotection was defined as a pre-vaccination and post-vaccination titer ≥ 1:40 (l/dil)</description>
        <time_frame>Day 21 post-vaccination</time_frame>
        <population>Seroprotection to vaccine antigens were determined in randomized and vaccinated participants, per-protocol population</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1 (Investigational Quadrivalent Influenza Vaccine)</title>
            <description>Participants aged 65 years and older who received the Investigational Quadrivalent Influenza Vaccine</description>
          </group>
          <group group_id="O2">
            <title>Group 2 (Investigational Trivalent Influenza Vaccine)</title>
            <description>Participants aged 65 years and older who received the Investigational Trivalent Influenza Vaccine</description>
          </group>
          <group group_id="O3">
            <title>Group 3 (Licensed Trivalent Influenza Vaccine)</title>
            <description>Participants aged 65 years and older who received the Licensed 2010-2011 Trivalent Influenza Vaccine</description>
          </group>
          <group group_id="O4">
            <title>Group 4 (Licensed Trivalent Influenza Vaccine)</title>
            <description>Participants aged 18 to less than 65 years who received the Licensed 2010-2011 Trivalent Influenza Vaccine</description>
          </group>
        </group_list>
        <measure>
          <title>Seroprotection Against Influenza Vaccine Antigens After Vaccination With Fluzone® Quadrivalent Influenza Vaccine or With Trivalent Influenza Vaccines in Participants Aged 18 Years or Older.</title>
          <description>Immunogenicity outcomes were assessed in serum samples by HAI assay. The lower limit of quantitation (LLOQ) was set at the lowest dilution used in the assay, 1/10. Titers below this level were reported as &lt;10.
Seroprotection was defined as a pre-vaccination and post-vaccination titer ≥ 1:40 (l/dil)</description>
          <population>Seroprotection to vaccine antigens were determined in randomized and vaccinated participants, per-protocol population</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="220"/>
                <count group_id="O2" value="221"/>
                <count group_id="O3" value="219"/>
                <count group_id="O4" value="59"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/H1N1 Pre-vaccination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70"/>
                    <measurement group_id="O2" value="70" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="78" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O4" value="27" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H1N1 Post-vaccination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="201"/>
                    <measurement group_id="O2" value="203" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="200" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O4" value="58" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2 Pre-vaccination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="129"/>
                    <measurement group_id="O2" value="119" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="131" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O4" value="27" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2 Post-vaccination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="220"/>
                    <measurement group_id="O2" value="212" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="209" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O4" value="57" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Brisbane Pre-vaccination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="101"/>
                    <measurement group_id="O2" value="108" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="108" lower_limit="25.0" upper_limit="33.7"/>
                    <measurement group_id="O4" value="21" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Brisbane Post-vaccination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="171"/>
                    <measurement group_id="O2" value="133" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="157" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O4" value="54" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Florida Pre-vaccination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75"/>
                    <measurement group_id="O2" value="67" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="68" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O4" value="18" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Florida Post-vaccination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="161"/>
                    <measurement group_id="O2" value="149" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="101" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O4" value="38" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Seroconversion Against Influenza Virus Antigens After Vaccination With Fluzone® Quadrivalent Influenza Vaccine or With Trivalent Influenza Vaccines in Participants Aged 18 Years and Older</title>
        <description>Immunogenicity outcomes were assessed in serum samples by HAI assay. The lower limit of quantitation (LLOQ) was set at the lowest dilution used in the assay, 1/10. Titers below this level were reported as &lt;10.
Seroconversion was defined as either a pre-vaccination HAI titer &lt;1:10 and a post-vaccination titer ≥1:40 or a pre-vaccination titer ≥1:10 and ≥ four-fold increase in post-vaccination titer.</description>
        <time_frame>Day 21 post-vaccination</time_frame>
        <population>Seroconversion to influenza vaccine antigens were determined in randomized and vaccinated participants, per-protocol population.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1 (Investigational Quadrivalent Influenza Vaccine)</title>
            <description>Participants aged 65 years and older who received the Investigational Quadrivalent Influenza Vaccine</description>
          </group>
          <group group_id="O2">
            <title>Group 2 (Investigational Trivalent Influenza Vaccine)</title>
            <description>Participants aged 65 years and older who received the Investigational Trivalent Influenza Vaccine</description>
          </group>
          <group group_id="O3">
            <title>Group 3 (Licensed Trivalent Influenza Vaccine)</title>
            <description>Participants aged 65 years and older who received the Licensed 2010-2011 Trivalent Influenza Vaccine</description>
          </group>
          <group group_id="O4">
            <title>Group 4 (Licensed Trivalent Influenza Vaccine)</title>
            <description>Participants aged 18 to less than 65 years who received the Licensed 2010-2011 Trivalent Influenza Vaccine</description>
          </group>
        </group_list>
        <measure>
          <title>Seroconversion Against Influenza Virus Antigens After Vaccination With Fluzone® Quadrivalent Influenza Vaccine or With Trivalent Influenza Vaccines in Participants Aged 18 Years and Older</title>
          <description>Immunogenicity outcomes were assessed in serum samples by HAI assay. The lower limit of quantitation (LLOQ) was set at the lowest dilution used in the assay, 1/10. Titers below this level were reported as &lt;10.
Seroconversion was defined as either a pre-vaccination HAI titer &lt;1:10 and a post-vaccination titer ≥1:40 or a pre-vaccination titer ≥1:10 and ≥ four-fold increase in post-vaccination titer.</description>
          <population>Seroconversion to influenza vaccine antigens were determined in randomized and vaccinated participants, per-protocol population.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="220"/>
                <count group_id="O2" value="221"/>
                <count group_id="O3" value="219"/>
                <count group_id="O4" value="59"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/A1N1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="145"/>
                    <measurement group_id="O2" value="161" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="146" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O4" value="46" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/A3N2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="152"/>
                    <measurement group_id="O2" value="139" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="122" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O4" value="50" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Brisbane/60/2008</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63"/>
                    <measurement group_id="O2" value="19" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="41" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O4" value="27" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Florida/04/2006</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73"/>
                    <measurement group_id="O2" value="69" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="20" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O4" value="18" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Participants Reporting Solicited Injection Site and Systemic Reactions After Vaccination With Fluzone® Quadrivalent Influenza Vaccine or With Trivalent Influenza Vaccines.</title>
        <description>Solicited injection site reactions: Pain, Erythema and Swelling; Solicited systemic reactions: Fever (Temperature), Headache, Malaise, and Myalgia.
Grade 3 Injection site reactions: Pain - Significant; prevents daily activity; Erythema and Swelling &gt;100 mm.
Grade 3 solicited systemic reactions: Fever (Temperature) ≥102.1°F; Headache, Malaise, and Myalgia - Significant; prevents daily activity.</description>
        <time_frame>Day 0 up to day 21 post-vaccination</time_frame>
        <population>Solicited injection site and systemic reactions were assessed in all randomized and vaccinated participants, safety population.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1 (Investigational Quadrivalent Influenza Vaccine)</title>
            <description>Participants aged 65 years and older who received the Investigational Quadrivalent Influenza Vaccine</description>
          </group>
          <group group_id="O2">
            <title>Group 2 (Investigational Trivalent Influenza Vaccine)</title>
            <description>Participants aged 65 years and older who received the Investigational Trivalent Influenza Vaccine</description>
          </group>
          <group group_id="O3">
            <title>Group 3 (Licensed Trivalent Influenza Vaccine)</title>
            <description>Participants aged 65 years and older who received the Licensed 2010-2011 Trivalent Influenza Vaccine</description>
          </group>
          <group group_id="O4">
            <title>Group 4 (Licensed Trivalent Influenza Vaccine)</title>
            <description>Participants aged 18 to less than 65 years who received the Licensed 2010-2011 Trivalent Influenza Vaccine</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Reporting Solicited Injection Site and Systemic Reactions After Vaccination With Fluzone® Quadrivalent Influenza Vaccine or With Trivalent Influenza Vaccines.</title>
          <description>Solicited injection site reactions: Pain, Erythema and Swelling; Solicited systemic reactions: Fever (Temperature), Headache, Malaise, and Myalgia.
Grade 3 Injection site reactions: Pain - Significant; prevents daily activity; Erythema and Swelling &gt;100 mm.
Grade 3 solicited systemic reactions: Fever (Temperature) ≥102.1°F; Headache, Malaise, and Myalgia - Significant; prevents daily activity.</description>
          <population>Solicited injection site and systemic reactions were assessed in all randomized and vaccinated participants, safety population.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="225"/>
                <count group_id="O2" value="225"/>
                <count group_id="O3" value="225"/>
                <count group_id="O4" value="64"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Injection site Pain (224, 225, 224, 63)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73"/>
                    <measurement group_id="O2" value="52" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="64" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O4" value="31" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Injection site Pain (224, 225, 224, 63)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O4" value="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site Erythema (224, 224, 224, 63)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="3" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="3" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O4" value="3" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Injection site Erythema (224, 224, 224, 63</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O4" value="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site Swelling (224, 224, 224, 63)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="3" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O4" value="5" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Injection site Swelling (224, 224, 224, 63</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O4" value="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever (224, 225, 223, 63)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O4" value="2" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Fever (224, 225, 223, 63)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O4" value="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache (224, 225, 224, 63)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30"/>
                    <measurement group_id="O2" value="26" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="26" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O4" value="16" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Headache (224, 225, 224, 63)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O4" value="1" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Malaise (224, 225, 224, 63)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="26" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="14" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O4" value="16" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade Malaise (224, 225, 224, 63)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O4" value="1" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Myalgia (224, 225, 224, 63)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41"/>
                    <measurement group_id="O2" value="32" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="41" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O4" value="22" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Myalgia (224, 225, 224, 63)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O4" value="1" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events data were collected from Day 0 (post-vaccination) upto 21 days post-vaccination</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Group 1 (Investigational Quadrivalent Influenza Vaccine)</title>
          <description>Participants aged 65 years and older who received the Investigational Quadrivalent Influenza Vaccine</description>
        </group>
        <group group_id="E2">
          <title>Group 2 (Investigational Trivalent Influenza Vaccine)</title>
          <description>Participants aged 65 years and older who received the Investigational Trivalent Influenza Vaccine</description>
        </group>
        <group group_id="E3">
          <title>Group 3 (Licensed Trivalent Influenza Vaccine)</title>
          <description>Participants aged 65 years and older who received the received the Licensed 2010-2011 Trivalent Influenza Vaccine</description>
        </group>
        <group group_id="E4">
          <title>Group 4 (Licensed Trivalent Influenza Vaccine)</title>
          <description>Participants aged 18 to less than 65 years who received the Licensed 2010-2011 Trivalent Influenza Vaccine</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA, version 13.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="225"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="225"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Retina detachment</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="225"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="225"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Malignant melanoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="225"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5.00</frequency_threshold>
        <default_vocab>MedDRA, version 13.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="73" subjects_at_risk="225"/>
                <counts group_id="E2" subjects_affected="52" subjects_at_risk="225"/>
                <counts group_id="E3" subjects_affected="64" subjects_at_risk="225"/>
                <counts group_id="E4" subjects_affected="31" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Injection site pain</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="73" subjects_affected="73" subjects_at_risk="224"/>
                <counts group_id="E2" events="52" subjects_affected="52" subjects_at_risk="225"/>
                <counts group_id="E3" events="64" subjects_affected="64" subjects_at_risk="224"/>
                <counts group_id="E4" events="31" subjects_affected="31" subjects_at_risk="63"/>
              </event>
              <event>
                <sub_title>Injection site Swelling</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="224"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="224"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="63"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" events="24" subjects_affected="24" subjects_at_risk="224"/>
                <counts group_id="E2" events="14" subjects_affected="14" subjects_at_risk="224"/>
                <counts group_id="E3" events="26" subjects_affected="26" subjects_at_risk="225"/>
                <counts group_id="E4" events="16" subjects_affected="16" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="41" subjects_affected="41" subjects_at_risk="224"/>
                <counts group_id="E2" events="32" subjects_affected="32" subjects_at_risk="225"/>
                <counts group_id="E3" events="41" subjects_affected="41" subjects_at_risk="224"/>
                <counts group_id="E4" events="22" subjects_affected="22" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="30" subjects_affected="30" subjects_at_risk="224"/>
                <counts group_id="E2" events="26" subjects_affected="26" subjects_at_risk="224"/>
                <counts group_id="E3" events="26" subjects_affected="26" subjects_at_risk="225"/>
                <counts group_id="E4" events="16" subjects_affected="16" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable subject matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Medical Director</name_or_title>
      <organization>Sanofi Pasteur Inc.</organization>
      <email>RegistryContactUs@sanofipasteur.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

